Logos Global Management LP Alx Oncology Holdings Inc Transaction History

Logos Global Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.37 - $9.56 $2.19 Million - $4.78 Million	-500,000 Reduced 33.33%	1,000,000 $7.51 Million
Q1 2023 May 15, 2023	SELL	$4.52 - $11.71 $3.84 Million - $9.95 Million	-849,600 Reduced 36.16%	1,500,000 $6.78 Million
Q4 2022 Feb 14, 2023	SELL	$9.51 - $12.95 $5.91 Million - $8.05 Million	-621,752 Reduced 20.92%	2,349,600 $26.5 Million
Q3 2022 Nov 14, 2022	SELL	$8.23 - $15.14 $1.36 Million - $2.5 Million	-165,000 Reduced 5.26%	2,971,352 $28.4 Million
Q2 2022 Aug 15, 2022	BUY	$5.89 - $19.46 $736,250 - $2.43 Million	125,000 Added 4.15%	3,136,352 $25.4 Million
Q1 2022 May 16, 2022	BUY	$13.65 - $22.06 $1.43 Million - $2.32 Million	105,000 Added 3.61%	3,011,352 $50.9 Million
Q4 2021 Feb 14, 2022	SELL	$21.49 - $74.4 $5.39 Million - $18.6 Million	-250,629 Reduced 7.94%	2,906,352 $62.5 Million
Q4 2020 Feb 16, 2021	BUY	$34.11 - $112.26 $682,200 - $2.25 Million	20,000 Added 0.64%	3,156,981 $272 Million
Q3 2020 Nov 16, 2020	BUY	$29.36 - $47.1 $92.1 Million - $148 Million	3,136,981 New	3,136,981 $118 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $68.9M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.